Quantum-computing-enhanced algorithm unveils potential KRAS inhibitors.

Area of Science:

• Quantum computing applications in drug discovery
• Computational chemistry for medicinal chemistry
• Oncology therapeutics development

Background:

• Targeting KRAS is crucial for cancer therapy, but developing effective inhibitors remains challenging.
• Classical computational methods have limitations in exploring novel chemical spaces for drug design.
• Quantum-classical approaches offer a new paradigm for molecular design.

Purpose of the Study:

• To introduce and apply a novel quantum-classical generative model for small-molecule design.
• To specifically target the design of KRAS inhibitors for cancer treatment.
• To validate the model's efficacy through experimental synthesis and testing.

Main Methods:

• Development of a hybrid quantum-classical generative algorithm.
• Application of the model to identify potential KRAS-engaging small molecules.
• In silico selection and subsequent experimental synthesis of 15 candidate molecules.

Main Results:

• The quantum-classical model successfully designed 15 novel small molecules.
• Two synthesized molecules demonstrated significant engagement with KRAS.
• Experimental validation confirmed the model's ability to generate promising drug candidates.

Conclusions:

• Quantum-classical generative models show significant potential for accelerating drug discovery.
• This work validates the use of quantum computing in generating experimentally relevant small molecules.
• The developed approach offers a competitive alternative to classical models for designing targeted cancer therapies.